Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxytocin + tibolone is a hypothetical combination of two distinct drugs, oxytocin and tibolone, each with separate mechanisms and indications. Oxytocin is a peptide hormone produced in the hypothalamus, primarily used to induce or augment labor, control postpartum hemorrhage, and facilitate milk letdown by stimulating uterine smooth muscle contraction. Tibolone is a synthetic steroid hormone used as menopausal hormone therapy; it acts as an agonist at estrogen, progesterone, and androgen receptors through its active metabolites. Tibolone relieves vasomotor symptoms (such as hot flushes), improves vaginal atrophy and sexual function in postmenopausal women, and helps prevent osteoporosis by mimicking the effects of endogenous sex hormones[3][4][5][6][8]. There are no known marketed products or clinical evidence for a fixed-dose combination of oxytocin with tibolone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxytocin + tibolone.